ESMO - Eur. Oncology· @myESMO · X·· 2 days agoScore90
Body · original
#ESMO26: Final results from the TALENT #ClinicalTrial show low pathological complete response rates with the antibody–drug conjugate (#ADC) trastuzumab deruxtecan in HR-positive, HER2-low #EarlyBreastCancer, as discussed by @breastDoktor #InsightsbyESMO
➡️ https://ow.ly/ZBwi50ZZXLm
1298 views · 9 likes · 6 reposts · 0 replies
Conference abstracts
LBA23matched by Proffered paper 1: Breast cancer, early and advanced stage
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.orgSource: ESMO - Eur. Oncology · x.com